Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%

MT Newswires Live

05/26

Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.

The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.

The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.

Shares of the pharma manufacturer were down over 3% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538121869"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538121869\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538121869?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-26 13:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538121869","market":"fut","top_or_hot":-1,"title":"Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.</p><p>The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.</p><p>The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.</p><p>Shares of the pharma manufacturer were down over 3% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharma's Demodex Blepharitis Treatment Approved in Macau; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-26 13:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.</p><p>The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.</p><p>The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.</p><p>Shares of the pharma manufacturer were down over 3% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"远大医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2538121869","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538121869","pubTimestamp":1748237333,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Grand Pharmaceutical Group  said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.Shares of the pharma manufacturer were down over 3% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药","BK1191":"制药"},"translate_title":"远大医药治疗蠕形螨睑缘炎在澳门获批；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9},"content_text":"Grand Pharmaceutical Group (HKG:0512) said its treatment for Demodex blepharitis, GPN01768, has been approved for sale in Macau, according to a Sunday Hong Kong bourse filing.The drug, licensed from Tarsus Pharmaceuticals, is the only FDA-approved therapy for the mite-related eyelid disease and generated $180 million in US sales in 2024. Grand Pharma holds exclusive rights in Greater China.The approval supports wider rollout in the Greater Bay Area and advances its push into mainland China.Shares of the pharma manufacturer were down over 3% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}